Dr. Nicole Reidy
In early August 2025, CurePSP hosted a webinar with Dr. Nicole Reidy, a clinical social worker, on the important and under-discussed topics of ambiguous loss and anticipatory grief. While the talk was aimed at caregivers of those with PSP, CBD, and MSA (under the “CurePSP umbrella”), everyone challenged by uncertainty and ongoing loss will find this talk of interest.
Mitchell Miglis, MD
On August 13, 2025, we co-hosted a webinar on orthostatic hypotension (orthostatic low blood pressure) in parkinsonian syndromes – Parkinson’s Disease, Multiple System Atrophy (MSA), and Lewy Body Dementia.
source: National Ataxia Foundation
The National Ataxia Foundation has a webpage devoted to the cerebellar type of multiple system atrophy (MSA-C):
credit: Margaret Manning
In this study done in the UK, there was a 48-week open label trial where 50 patients with MSA participated — half received exenatide, a GLP-1 receptor agonist, and half did not. An “open label trial” is one in which both the participants and the researchers know if they are receiving the medication or not. (This is in contrast to a “double-blind trial.”)
This is an interesting little study done in Japan. Researchers say that they can differentiate those with multiple system atrophy (MSA) from Parkinson’s disease (PD) based on the surface temperature of a finger that has been placed in cold water for 10 seconds. The temperature of those with PD recovered more slowly as compared to MSA.
